A panel of experts discuss basal cell carcinoma and cutaneous squamous cell carcinoma therapeutic agents in depth as they analyze clinical case scenarios.
EP. 1: Clinical Presentation of Basal Cell Carcinoma
Richard Bakst, MD, and Ezra Cohen, MD, FRCPSC, FASCO, explain what the typical clinical presentation of basal cell carcinoma will look like in a patient.
EP. 2: Clinical Case 1 Scenario and Surgical Options for Basal Cell Carcinoma
Kevin Emerick, MD, analyzes the data from the first clinical case scenario and touches upon potential surgical options for patients with similar diagnoses.
EP. 3: Treatment Options for Basal Cell Carcinoma
Drs Emerick and Bakst continue to speak on the data from the first clinical case scenario and highlight other treatment options.
EP. 4: Hedgehog Inhibitors and Basal Cell Carcinoma
Ezra Cohen, MD, FRCPSC, FASCO, and Gino K. In, MD, MPH, elaborate on the role hedgehog inhibitors can play when treating patients with basal cell carcinoma.
EP. 5: Immunotherapy in Basal Cell Carcinoma
Two experts provide their thoughts on phase 2 data concerning the use of cemiplimab for treating locally advanced basal cell carcinoma.
EP. 6: Incidence of Cutaneous Squamous Cell Carcinoma
Starting the discussion on cutaneous squamous cell carcinoma, Dr Emerick provides insight on signs to look for, as well as risk factors.
EP. 7: Radiation Approaches for CSCC and Standard of Care
Dr Bakst comments on radiation treatment therapies and the standard of care for cutaneous squamous cell carcinoma.
EP. 8: Clinical Case 2 Scenario
Drs In and Emerick analyze the data from our second clinical case scenario and tell us what they would do if it were their patient.
EP. 9: Clinical Case 2 Continued
Drs Bakst and Cohen close out our second clinical case scenario by providing their thoughts on potential radiation therapy and using cemiplimab.
EP. 10: KEYNOTE-629 Trial and Pembrolizumab
Dr In comments on data from the KEYNOTE-629 trial that focused on the use of pembrolizumab as a therapy option for patients with cutaneous squamous cell carcinoma.
EP. 11: Using Other Therapies and the Future of Systemic Therapy for the Treatment of Advanced CSCC
Drs In, Cohen, and Bakst discuss the use of other therapies for cutaneous squamous cell carcinoma, as well as what they believe is the future of systemic therapy for this disease.
EP. 12: Clinical Case 3 Scenario
Our final clinical case scenario is presented, and Kevin Emerick, MD, uses his experience to determine a proper course of action.
EP. 13: Neoadjuvant Immuno-oncology in the Treatment of Locally Advanced CSCC
Our discussion closes with the presentation of phase 2 clinical trial data of neoadjuvant cemiplimab in locally regionally advanced cutaneous squamous cell carcinoma.
IDE397 Shows Early Antitumor Activity, Safety in MTAP-Deletion Urothelial Cancer and NSCLC
RVU120 Shows Early Promise in R/R Metastatic or Advanced Solid Tumors
The WEE1 Inhibitor APR-1051 Shows Early Safety and Tolerability in Advanced, Mutated Solid Tumors
TYRA-300 Is Safe, Generates Preliminary Antitumor Activity in FGFR3+ Metastatic Urothelial Cancer